Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks to move beyond its reliance on the fading market for Covid-19 shots ...
Synopsys VC Verification IP (VIP) for Fibre Channel is designed to thoroughly verify Fibre Channel designs using both random and directed simulation. The Fibre Channel VIP provides full protocol ...
Moderna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved ...
A Food and Drug Administration expert panel voted Wednesday to manufacture new COVID-19 vaccines to specifically target the JN.1 variant lineage—which makes up the most dominant strains ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
COVID-19 vaccine maker Moderna (NASDAQ:MRNA) announced Friday that the U.S. Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345), its messenger-based vaccine to protect older adults ...
WASHINGTON — Government advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall -- targeting a version of the ever-evolving ...
A researcher at the Moderna headquarters in Cambridge, Mass. (Adam Glanzman/Bloomberg News) Moderna, the biotech that rose to fame for making one of the world’s first Covid-19 vaccines, has hit ...
First mRNA vaccine approved for a disease other than COVID Moderna Inc.'s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking ...